Date: 4/4/2022 Your Name: Kathleen Aren Manuscript Title: RNA-Seq analysis identifies novel roles for alterations of the primary cilia gene SPAG17 and SOX9 locus non-coding RNAs in systemic sclerosis Manuscript number (if known): ar-21-1823

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	<u>x</u> None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	<u>x</u> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u> </u>	
4	Consulting fees	<u>x</u> None	

	1	
_		
5	Payment or honoraria for	<u>_x_</u> None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert testimony	_ <u>x</u> _None
7	Support for attending meetings and/or travel	<u>x</u> None
8	Patents planned, issued or	<u>x</u> None
	pending	
9	Participation on a Data	x_None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	<u>x</u> None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	x_None
12	Receipt of equipment,	<u>x</u> None
1	materials, drugs, medical	
	writing, gifts or other	
	services	
13	Other financial or non-	<u>x</u> None
	financial interests	
-	•	

Date: 4/4/2022 Your Name: John P. Atkinson Manuscript Title: RNA-Seq analysis identifies novel roles for alterations of the primary cilia gene SPAG17 and SOX9 locus non-coding RNAs in systemic sclerosis Manuscript number (if known): ar-21-1823

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<u>x</u> None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>x</u> None	
3	Royalties or licenses	<u>x</u> None	
4	Consulting fees	<u>x</u> None	

	1	
_		
5	Payment or honoraria for	<u>_x_</u> None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert testimony	_ <u>x</u> _None
7	Support for attending meetings and/or travel	<u>x</u> None
8	Patents planned, issued or	<u>x</u> None
	pending	
9	Participation on a Data	x_None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	<u>x</u> None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	x_None
12	Receipt of equipment,	<u>x</u> None
1	materials, drugs, medical	
	writing, gifts or other	
	services	
13	Other financial or non-	<u>x</u> None
	financial interests	
-	•	

Date: 4/4/2022 Your Name: Li Cao Manuscript Title: RNA-Seq analysis identifies novel roles for alterations of the primary cilia gene SPAG17 and SOX9 locus non-coding RNAs in systemic sclerosis Manuscript number (if known): ar-21-1823

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	<u>x</u> None	
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	<u>x</u> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>x</u> None	
4	Consulting fees	<u>x</u> None	

	1	
_		
5	Payment or honoraria for	<u>_x_</u> None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert testimony	_ <u>x</u> _None
7	Support for attending meetings and/or travel	<u>x</u> None
8	Patents planned, issued or	<u>x</u> None
	pending	
9	Participation on a Data	x_None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	<u>x</u> None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	x_None
12	Receipt of equipment,	<u>x</u> None
1	materials, drugs, medical	
	writing, gifts or other	
	services	
13	Other financial or non-	<u>x</u> None
	financial interests	
-	•	

Date: 4/4/2022 Your Name: Mary Carns Manuscript Title: RNA-Seq analysis identifies novel roles for alterations of the primary cilia gene SPAG17 and SOX9 locus non-coding RNAs in systemic sclerosis Manuscript number (if known): ar-21-1823

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	<u>x</u> None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	<u>x</u> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>x</u> None	
4	Consulting fees	<u>x</u> None	

	1	
_		
5	Payment or honoraria for	<u>_x_</u> None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert testimony	_ <u>x</u> _None
7	Support for attending meetings and/or travel	<u>x</u> None
8	Patents planned, issued or	<u>x</u> None
	pending	
9	Participation on a Data	x_None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	<u>x</u> None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	x_None
12	Receipt of equipment,	<u>x</u> None
1	materials, drugs, medical	
	writing, gifts or other	
	services	
13	Other financial or non-	<u>x</u> None
	financial interests	
-	•	

Date: 4/4/2022 Your Name: Isaac Goldberg Manuscript Title: RNA-Seq analysis identifies novel roles for alterations of the primary cilia gene SPAG17 and SOX9 locus non-coding RNAs in systemic sclerosis Manuscript number (if known): ar-21-1823

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	<u>x</u> None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	<u>x</u> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u> </u>	
4	Consulting fees	<u>x</u> None	

	1	
_		
5	Payment or honoraria for	<u>_x_</u> None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert testimony	_ <u>x</u> _None
7	Support for attending meetings and/or travel	<u>x</u> None
8	Patents planned, issued or	<u>x</u> None
	pending	
9	Participation on a Data	x_None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	<u>x</u> None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	x_None
12	Receipt of equipment,	<u>x</u> None
1	materials, drugs, medical	
	writing, gifts or other	
	services	
13	Other financial or non-	<u>x</u> None
	financial interests	
-	•	

Date: 4/4/2022 Your Name: Benjamin Korman Manuscript Title: RNA-Seq analysis identifies novel roles for alterations of the primary cilia gene SPAG17 and SOX9 locus non-coding RNAs in systemic sclerosis Manuscript number (if known): ar-21-1823

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	<u>x</u> None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	<u>x</u> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u> </u>	
4	Consulting fees	<u>x</u> None	

	1	
_		
5	Payment or honoraria for	<u>_x_</u> None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert testimony	_ <u>x</u> _None
7	Support for attending meetings and/or travel	<u>x</u> None
8	Patents planned, issued or	<u>x</u> None
	pending	
9	Participation on a Data	x_None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	<u>x</u> None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	x_None
12	Receipt of equipment,	<u>x</u> None
1	materials, drugs, medical	
	writing, gifts or other	
	services	
13	Other financial or non-	<u>x</u> None
	financial interests	
-	•	

Date: March 30, 2022 Your Name: David Morales-Heil Manuscript Title: RNA-Seq analysis identifies novel roles for alterations of the primary cilia gene SPAG17 and SOX9 locus non-coding RNAs in systemic sclerosis Manuscript number (if known): ar-21-1823

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	<u>x</u> None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	<u>x</u> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>x</u> None	
4	Consulting fees	<u>x</u> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_ <u>x</u> _None	
6	Payment for expert testimony	<u>x</u> _None	
7	Support for attending meetings and/or travel	_ <u>x</u> None	
8	Patents planned, issued or pending	<u>x</u> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ <u>x_</u> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u>x</u> None	
11	Stock or stock options	Pfizer	At the time of contribution to the manuscript I was a post-doctoral fellow at Washington University. After completion of my post-doc I became an employee of Pfizer.
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u>x</u> None	
13	Other financial or non- financial interests	Pfizer	At the time of contribution to manuscript I was a post- doc at Washington University. After completion of post- doctoral fellowship I became an employee at Pfizer.

Date: 4/4/2022 Your Name: Elisha D.O. Roberson Manuscript Title: RNA-Seq analysis identifies novel roles for alterations of the primary cilia gene SPAG17 and SOX9 locus non-coding RNAs in systemic sclerosis Manuscript number (if known): ar-21-1823

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<u>x</u> None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_xNone	
3	Royalties or licenses	<u>x</u> None	
4	Consulting fees	<u>x</u> None	

_		
5	Payment or honoraria for	_ <u>x_</u> None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	_ <u>x</u> None
	testimony	
7	Support for attending meetings and/or travel	<u>x</u> None
8	Patents planned, issued or	<u>x</u> None
	pending	
9	Participation on a Data Safety Monitoring Board or	x None
	Advisory Board	
10	Leadership or fiduciary role in other board, society,	x None
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	x None
12	Receipt of equipment,	x None
1	materials, drugs, medical	
	writing, gifts or other	
1	services	
13	Other financial or non-	x None
	financial interests	

Date: 4/4/2022 Your Name: John Varga Manuscript Title: RNA-Seq analysis identifies novel roles for alterations of the primary cilia gene SPAG17 and SOX9 locus non-coding RNAs in systemic sclerosis Manuscript number (if known): ar-21-1823

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	<u>x</u> None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	<u>x</u> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u> </u>	
4	Consulting fees	<u>x</u> None	

_		
5	Payment or honoraria for	_ <u>x_</u> None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	_ <u>x</u> None
	testimony	
7	Support for attending meetings and/or travel	<u>x</u> None
8	Patents planned, issued or	<u>x</u> None
	pending	
9	Participation on a Data Safety Monitoring Board or	x None
	Advisory Board	
10	Leadership or fiduciary role in other board, society,	x None
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	x None
12	Receipt of equipment,	x None
1	materials, drugs, medical	
	writing, gifts or other	
1	services	
13	Other financial or non-	x None
	financial interests	